Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

SGX:T14 Revenue

Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.02B CNY in the quarter ending September 30, 2025, a decrease of -38.08%. This brings the company's revenue in the last twelve months to 5.37B, down -33.26% year-over-year. In the year 2024, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 7.31B, down -11.14%.

• Revenue (ttm): 5.37B CNY
• Revenue Growth: -33.26%
• P/S Ratio: 5.61
• Revenue / Employee: 1.16M CNY
• Employees: 4,619
• Market Cap: 5.46B SGD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	7.31B	-915.58M	-11.14%
Dec 31, 2023	8.22B	-26.94M	-0.33%
Dec 31, 2022	8.25B	1.34B	19.42%
Dec 31, 2021	6.91B	303.89M	4.60%
Dec 31, 2020	6.60B	-390.23M	-5.58%